Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 19/20 | 0.50 |
| ▸ | FLT1 | P17948 | 4/20 | 0.50 |
| ▸ | EGLN3 | Q9H6Z9 | 4/20 | 0.50 |
| ▸ | VEGFA | P15692 | 3/20 | 0.50 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.46 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30546885 | 1.00 | EGLN1 (0.50) | EGLN1FLT1EGLN3VEGFAEGLN2 | |
| SCHEMBL24257682 | 0.88 | EGLN3 (0.55) | EGLN1FLT1EGLN3VEGFAEGLN2 | |
| SCHEMBL30546862 | 0.88 | EGLN3 (0.55) | EGLN1FLT1EGLN3VEGFAEGLN2 | |
| SCHEMBL30453195 | 0.86 | CASP1 (0.49) | EGLN1FLT1EGLN3VEGFA | |
| SCHEMBL24257534 | 0.86 | CASP1 (0.49) | EGLN1FLT1EGLN3VEGFA | |
| SCHEMBL24257601 | 0.85 | EGLN1 (0.56) | EGLN1FLT1EGLN3VEGFAEGLN2 | |
| SCHEMBL30546834 | 0.85 | EGLN1 (0.56) | EGLN1FLT1EGLN3VEGFAEGLN2 | |
| SCHEMBL24257636 | 0.84 | EGLN1 (0.51) | EGLN1FLT1EGLN3VEGFAFTO | |
| SCHEMBL30452742 | 0.84 | EGLN1 (0.51) | EGLN1FLT1EGLN3VEGFAFTO | |
| Formic Acid SCHEMBL30453154 | 0.84 | EGLN3 (0.52) | EGLN1FLT1EGLN3VEGFAEGLN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295110-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230295110-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| CN-116670131-A | PHD inhibitor compounds, compositions, and methods of use | 阿克比治疗有限公司 | 2023-08-29 | — | — | CN | disclosed |
| WO-2022036188-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295110-A1 | PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | HIF1AN, EGLN3, PHF20 | EGLN1 19/4885FLT1 414/4885EGLN3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.